BEGIN:VCALENDAR
VERSION:2.0
PRODID:-//www.insightmcc.org//NONSGML kigkonsult.se iCalcreator 2.30.10//
CALSCALE:GREGORIAN
METHOD:PUBLISH
UID:9b0e3c3a-6ccd-4608-a853-918f930a05a7
X-WR-CALDESC:The U.S. Food and Drug Administration has approved Kisunla (do
 nanemab-azbt) injection for the treatment of Alzheimer’s disease. Treatmen
 t with Kisunla should be initiated in patients with mild cognitive impairm
 ent or mild dementia stage of disease\, the population in which treatment 
 was studied in the clinical trials. Dr. Pauldurai will talk about the new 
 drug\, benefits\, and answer questions you may have about it. \n\nPlease r
 egister and you will receive Zoom information prior to the class.\n\n<b>Pr
 esenter</b> \n<i> Dr. Jennifer Pauldurai\, MD </i>\nDr. Jennifer Pauldurai
  is a specialty care physician board certified in neurology and board elig
 ible in neuropsychiatry at Inova Health System. She joined Inova in 2023 a
 nd has been practicing since 2019. Prior to joining Inova\, Dr. Pauldurai 
 was a behavioral neurology and neuropsychiatry fellow at Lou Ruvo Center f
 or Brain Health\, Cleveland Clinic in Las Vegas. Dr. Pauldurai’s clinical 
 areas of interest include memory disorders\, dementia syndromes\, behavior
 al disruptions including hallucinations and delusions\, and mood disorders
  in the setting of neurodegenerative disease. \n\n&nbsp\;\n<strong><a href
 ='https://insightmemory.app.neoncrm.com/eventReg.jsp?event=1854&' target='
 _blank' class='button' rel='noreferrer noopener'>Sign Me Up!</a></strong>
X-WR-RELCALID:d113f705858a9edaae8ea376982dee2f
X-WR-TIMEZONE:America/New_York
BEGIN:VTIMEZONE
TZID:America/New_York
BEGIN:STANDARD
TZNAME:EST
DTSTART:20231105T020000
TZOFFSETFROM:-0400
TZOFFSETTO:-0500
RDATE:20241103T020000
RDATE:20251102T020000
END:STANDARD
BEGIN:DAYLIGHT
TZNAME:EDT
DTSTART:20240310T020000
TZOFFSETFROM:-0500
TZOFFSETTO:-0400
RDATE:20250309T020000
END:DAYLIGHT
END:VTIMEZONE
BEGIN:VEVENT
UID:7fe5ead7-238b-4b90-a70c-410dd1c04a28
DTSTAMP:20260421T155405Z
DESCRIPTION:The U.S. Food and Drug Administration has approved Kisunla (don
 anemab-azbt) injection for the treatment of Alzheimer’s disease. Treatment
  with Kisunla should be initiated in patients with mild cognitive impairme
 nt or mild dementia stage of disease\, the population in which treatment w
 as studied in the clinical trials. Dr. Pauldurai will talk about the new d
 rug\, benefits\, and answer questions you may have about it. \n\nPlease re
 gister and you will receive Zoom information prior to the class.\n\n<b>Pre
 senter</b> \n<i> Dr. Jennifer Pauldurai\, MD </i>\nDr. Jennifer Pauldurai 
 is a specialty care physician board certified in neurology and board eligi
 ble in neuropsychiatry at Inova Health System. She joined Inova in 2023 an
 d has been practicing since 2019. Prior to joining Inova\, Dr. Pauldurai w
 as a behavioral neurology and neuropsychiatry fellow at Lou Ruvo Center fo
 r Brain Health\, Cleveland Clinic in Las Vegas. Dr. Pauldurai’s clinical a
 reas of interest include memory disorders\, dementia syndromes\, behaviora
 l disruptions including hallucinations and delusions\, and mood disorders 
 in the setting of neurodegenerative disease. \n\n&nbsp\;\n<strong><a href=
 'https://insightmemory.app.neoncrm.com/eventReg.jsp?event=1854&' target='_
 blank' class='button' rel='noreferrer noopener'>Sign Me Up!</a></strong>
DTSTART;TZID=America/New_York:20240827T190000
DTEND;TZID=America/New_York:20240827T200000
LOCATION:Virtual! Zoom link provided upon registration.
SUMMARY:New Alzheimer's Medication: Kisunla - What You Need to Know (Virtua
 l)
END:VEVENT
END:VCALENDAR